Sanofi (SNY)

55.15 +0.30 (+0.55%) At close: 04:00PM EDT

Sanofi

46, avenue de la Grande Armée,
Paris 75017
France
33 1 53 77 40 00
https://www.sanofi.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 86,088

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul Hudson	CEO & Director	4.24M	N/A	1967
Mr. François-Xavier Roger	Executive VP & CFO	N/A	N/A	1962
Ms. Madeleine Roach	Executive VP & Head of Business Operations	N/A	N/A	1984
Mr. Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	N/A	N/A	N/A
Dr. Josephine Fubara	Chief Science Officer of Consumer Health Care	N/A	N/A	N/A
Mr. Thomas Kudsk Larsen	Head of Investor Relations	N/A	N/A	1974
Mr. Dante Beccaria	Global Compliance Officer & VP	N/A	N/A	N/A
Mr. Roy Papatheodorou	Executive VP & General Counsel	N/A	N/A	1978
Mr. Josep Catlla	Head of Communications	N/A	N/A	N/A
Mr. Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	N/A	N/A	1957

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Corporate governance

Sanofi’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.